Amgen has reported a 45.9% decrease in net income to $746m in the second quarter (Q2) of 2024 compared to $1.3bn in the same period of the previous year.
Despite this decline, the company’s total revenues saw a 20% increase to $8.4bn in comparison to $6.6bn in Q2 2023.
Go deeper with GlobalData
Product sales rose by 20%, attributed to a 26% increase in volume, which was partially offset by a 3% decrease in net selling price.
Excluding sales from the Horizon acquisition, product sales of the company grew by 5%, with volume growth of 10%.
Amgen noted that 12 products, including Prolia, EVENITY, Repatha, TEZSPIRE and TAVNEOS achieved at least double-digit sales growth in the quarter.
For the three months ended 30 June 2024, generally accepted accounting principles (GAAP) earnings per share (EPS) decreased by 46% to $1.38 from $2.57 in Q2 2023.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThis was attributed to increased operating expenses, including those related to amortisation, from Horizon-acquired assets and Horizon’s incremental expenses, though partially offset by higher revenues.
GAAP operating income fell to $1.9bn from $2.7bn in the prior year quarter, with the operating margin dropping 16.5 percentage points to 23.7%.
Non-GAAP EPS saw a slight decrease of 1% to $4.97 from $5.0 in Q2 2023.
Non-GAAP operating income rose from $3.5bn to $3.9bn, while the operating margin decreased by 4.4 percentage points to 48.2%.
The company declared a second-quarter dividend of $2.25 per share on 6 March 2024 – a 6% increase from the same period in 2023.
Amgen chairman and CEO Robert Bradway stated: “With a strong, balanced portfolio of in-market products and a rapidly advancing pipeline of innovative medicines, we are confident in our ability to deliver attractive long-term growth.”
The company has updated its guidance for the full year of 2024 and now expects total revenues between $32.8bn and $33.8bn.
On a GAAP basis, EPS is projected to be between $6.57 and $7.62 with a tax rate between 6% and 7.5%.
On a non-GAAP basis, EPS is estimated to be between $19.10 and $20.10, with a tax rate of 15% to 16%.
In May 2024, Amgen reported that total revenues grew in Q1 2024 to $7.4bn, displaying a 22% increase from earnings reported in Q1 2023.
